Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464-471. doi:10.1038/nature24644.

Canver MC, Haeussler M, Bauer DE, et al. Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments. Nat Protoc. 2018;13(5):946-986. doi:10.1038/nprot.2018.005.

Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418. doi:10.1038/nature23270.

Xu Y-X, Redon V, Yu H, et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis. 2018;268:196-206. doi:10.1016/j.atherosclerosis.2017.08.031.

Gupta M, Concepcion CP, Fahey CG, et al. BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. Cancer Res. 2020;80(18):3841-3854. doi:10.1158/0008-5472.CAN-20-1744.

Abadi S, Yan WX, Amar D, Mayrose I. A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action. PLoS Comput Biol. 2017;13(10):e1005807. doi:10.1371/journal.pcbi.1005807.

Doench JG. Am I ready for CRISPR? A user’s guide to genetic screens. Nat Rev Genet. 2018;19(2):67-80. doi:10.1038/nrg.2017.97.

Lee JW, T Y Chan C, Slomovic S, Collins JJ. Next-generation biocontainment systems for engineered organisms. Nat Chem Biol. 2018;14(6):530-537. doi:10.1038/s41589-018-0056-x.

Hazelbaker DZ, Beccard A, Bara AM, et al. A Scaled Framework for CRISPR Editing of Human Pluripotent Stem Cells to Study Psychiatric Disease. Stem Cell Reports. 2017;9(4):1315-1327. doi:10.1016/j.stemcr.2017.09.006.

Pyzocha NK, Chen S. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications. ACS Chem Biol. 2018;13(2):347-356. doi:10.1021/acschembio.7b00800.